Annals of the American Thoracic Society · 2026
Mental health diagnosis and medication changes after initiation of elexacaftor/tezacaftor/ivacaftor.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McKinzie Cameron J, Tak Casey R, Duehlmeyer Stephanie, Foushee Sarah, Hua Suzan, Jones Morgan C, Pettit Rebecca S, Shi Yi, Tillman Emma M, Wright Brittany A, Kam Charissa W
Аннотация
RATIONALE: Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with varied effects on mental health (MH) in people with cystic fibrosis (PwCF). Currently published literature has focused primarily on MH diagnoses/symptoms with ETI as opposed to associated pharmacotherapy.
OBJECTIVES: We sought to evaluate the effect of ETI on MH diagnosis and associated pharmacotherapy in both adult and pediatric PwCF.
METHODS: We conducted a multicenter retrospective study in PwCF who started ETI at 7 accredited cystic fibrosis centers. Primary outcomes were the rate of MH diagnosis and medication use pre- and post-ETI initiation. Secondary outcomes were the rate of MH medication changes and dose adjustments pre- and post-ETI.
MEASUREMENTS AND MAIN RESULTS: Overall, 1046 PwCF were included, with 453 in the "MH group" because they had either an MH diagnosis and/or MH medication use at any time point post-ETI. Mental health medication use and diagnosis both significantly increased from baseline at all time points post-ETI initiation.
CONCLUSIONS: The rate of MH medication use increased significantly from baseline at all time points in PwCF not previously prescribed MH medications, while rate of MH medication use remained consistent for those already on medications pre-ETI.
OBJECTIVES: We sought to evaluate the effect of ETI on MH diagnosis and associated pharmacotherapy in both adult and pediatric PwCF.
METHODS: We conducted a multicenter retrospective study in PwCF who started ETI at 7 accredited cystic fibrosis centers. Primary outcomes were the rate of MH diagnosis and medication use pre- and post-ETI initiation. Secondary outcomes were the rate of MH medication changes and dose adjustments pre- and post-ETI.
MEASUREMENTS AND MAIN RESULTS: Overall, 1046 PwCF were included, with 453 in the "MH group" because they had either an MH diagnosis and/or MH medication use at any time point post-ETI. Mental health medication use and diagnosis both significantly increased from baseline at all time points post-ETI initiation.
CONCLUSIONS: The rate of MH medication use increased significantly from baseline at all time points in PwCF not previously prescribed MH medications, while rate of MH medication use remained consistent for those already on medications pre-ETI.